VRTX Q3 2025 Earnings — Vertex Pharmaceuticals Incorporated Revenue & Financial Results | Market Cap Arena

VRTXVertex Pharmaceuticals Incorporated

$129B

Q3 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$3.1B+11.0% YoY

Gross Profit

$2.7B86.5% margin

Operating Income

$1.2B38.6% margin

Net Income

$1.1B35.2% margin

EPS (Diluted)

$4.20

QoQ Revenue Growth

+3.8%

Cash Flow

Operating Cash Flow

$1.2B

Free Cash Flow

$1.1B

Stock-Based Comp.

$195M

Balance Sheet

Total Assets

$24.9B

Total Liabilities

$7.5B

Stockholders' Equity

$17.3B

Cash & Equivalents

$4.9B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$3.1B	$2.8B	+11.0%
Gross Profit	$2.7B	$2.4B	+11.9%
Operating Income	$1.2B	$1.1B	+6.3%
Net Income	$1.1B	$1.0B	+3.6%

Revenue Segments

TRIKAFTA/KAFTRIO

$2.7B86%

ALYFTREK

$247M8%

Manufactured Product, Other

$176M6%

Geographic Segments

UNITED STATES

$2.0B47%

Non-US

$1.4B33%

Europe

$837M20%